Shimbu K, Hisakane K, Kadoma N, Nishima S, Atsumi K, Seike M
Onco Targets Ther. 2024; 17:717-726.
PMID: 39234190
PMC: 11371895.
DOI: 10.2147/OTT.S475836.
Ito T, Tsuchiya K, Mori R, Akashi T, Oyama Y, Ikeda M
Respir Med Case Rep. 2024; 49:102029.
PMID: 38712314
PMC: 11070756.
DOI: 10.1016/j.rmcr.2024.102029.
Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S
Target Oncol. 2024; 19(3):423-433.
PMID: 38613731
PMC: 11111546.
DOI: 10.1007/s11523-024-01048-x.
Ikeo S, Yasuda N, Sakai Y, Hayashi Y, Sokai A, Iwata T
Thorac Cancer. 2023; 14(10):958-960.
PMID: 36810936
PMC: 10067352.
DOI: 10.1111/1759-7714.14831.
Gu J, Bai F, Song L, Wang Y
Zhongguo Fei Ai Za Zhi. 2021; 24(11):804-807.
PMID: 34802213
PMC: 8607285.
DOI: 10.3779/j.issn.1009-3419.2021.102.39.
Successful treatment with afatinib following the failure of osimertinib rechallenge with osimertinib-induced interstitial lung disease: A case report.
Sato Y, Sekine A, Hagiwara E, Sato M, Yamaya T, Asaoka M
Respir Med Case Rep. 2021; 33:101450.
PMID: 34401289
PMC: 8349001.
DOI: 10.1016/j.rmcr.2021.101450.
Osimertinib rechallenge under steroid protection following osimertinib-induced pneumonitis: three case studies.
Bickert C, Kahnert K, Kauffmann-Guerrero D, Gotschke J, Syunyaeva Z, Behr J
Ther Adv Med Oncol. 2021; 13:17588359211018028.
PMID: 34178120
PMC: 8202262.
DOI: 10.1177/17588359211018028.
Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.
Nishima S, Miyanaga A, Saito S, Yuasa M, Takahashi S, Kashiwada T
Intern Med. 2020; 60(4):591-594.
PMID: 32999231
PMC: 7946498.
DOI: 10.2169/internalmedicine.5435-20.
Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T
Invest New Drugs. 2020; 39(2):571-577.
PMID: 32955628
DOI: 10.1007/s10637-020-01005-1.
Successful osimertinib retreatment after extremely early onset severe pneumonitis in first-line treatment of lung adenocarcinoma.
Ahn J
Thorac Cancer. 2020; 11(9):2713-2716.
PMID: 32666714
PMC: 7471046.
DOI: 10.1111/1759-7714.13565.
Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.
Lu H, Dowell J
In Vivo. 2019; 34(1):315-319.
PMID: 31882494
PMC: 6984067.
DOI: 10.21873/invivo.11776.
Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review.
Itano J, Higo H, Ohashi K, Makimoto G, Nishii K, Hotta K
Intern Med. 2019; 59(6):823-828.
PMID: 31787696
PMC: 7118377.
DOI: 10.2169/internalmedicine.3689-19.
Late-onset severe pneumonitis under osimertinib.
Syunyaeva Z, Berghof K, Kauffmann-Guerrero D, Gotschke J, Tufman A, Kahnert K
AME Case Rep. 2019; 3:39.
PMID: 31728437
PMC: 6851417.
DOI: 10.21037/acr.2019.09.01.
Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma.
Satoh S, Shiroyama T, Tamiya M, Nasu S, Tanaka A, Morita S
Respir Med Case Rep. 2018; 23:68-70.
PMID: 29487786
PMC: 5805846.
DOI: 10.1016/j.rmcr.2017.12.005.